InnoCare Pharma and KeyMed Partner with Prolium Bioscience for Exclusive License Agreement

  • InnoCare Pharma and KeyMed Biosciences have entered an exclusive license agreement with Prolium Bioscience for the development of ICP-B02.
  • The deal includes payments of up to $520 million, with potential royalties based on future sales.

InnoCare Pharma and KeyMed Biosciences have announced an exclusive partnership with Prolium Bioscience to develop and commercialise ICP-B02 (CM355), a promising CD20xCD3 bispecific antibody. This agreement covers the non-oncology field globally and the oncology field in regions outside of Asia.

ICP-B02 is designed to bind to CD20 on tumour cells and CD3 on T cells, redirecting and activating T cells to eliminate tumour cells through T-cell Directed Cellular Cytotoxicity (TDCC). The therapy has shown strong potential in both oncology and non-oncology applications.

The agreement will see Prolium obtaining exclusive rights to develop, manufacture, and commercialise ICP-B02 in the specified regions. InnoCare and KeyMed will receive aggregate payments of up to $520 million, including upfront payments and additional amounts tied to the achievement of clinical, regulatory, and commercial milestones. Additionally, they will acquire a minority equity stake in Prolium and be entitled to tiered royalties on future net sales.

Prolium is supported by RTW Investments, LP, a global investment firm that identifies disruptive innovations in the biopharmaceutical and medical technology sectors. This partnership positions InnoCare and KeyMed to benefit from Prolium’s expertise in the global biopharmaceutical market.

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.